(Q43760953)

26 November 2017

title

Impact of HIV-1 replication on immunological evolution during long-term dual-boosted protease inhibitor therapy (English)

1 reference

26 November 2017

1 reference

4

Nils von Hentig

0 references

Martin Stürmer

object named as

Martin Stürmer

9

0 references

Annemarie Berger

10

object named as

Annemarie Berger

1 reference

26 November 2017

Christoph Stephan

1

1 reference

26 November 2017

Valentin Bartha

2

1 reference

26 November 2017

Eva Herrmann

3

1 reference

26 November 2017

Nils von Hentig

4

1 reference

26 November 2017

Pavel Khaykin

5

1 reference

26 November 2017

Gaby Knecht

6

1 reference

26 November 2017

Peter Gute

7

1 reference

26 November 2017

Hans-Reinhard Brodt

8

1 reference

26 November 2017

Markus Bickel

11

1 reference

26 November 2017

publication date

15 September 2012

1 reference

Medical Microbiology and Immunology

26 November 2017

published in

1 reference

26 November 2017

volume

202

1 reference

26 November 2017

issue

2

1 reference

26 November 2017

page(s)

117-124

1 reference

Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0276-8

High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0276-8

Raltegravir, etravirine, and ritonavir-boosted darunavir: a safe and successful rescue regimen for multidrug-resistant HIV-1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0276-8

Class-sparing regimens for initial treatment of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0276-8

Increased reporting of detectable plasma HIV-1 RNA levels at the critical threshold of 50 copies per milliliter with the Taqman assay in comparison to the Amplicor assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0276-8

Modifications and substitutions of the RNA extraction module in the ViroSeq HIV-1 genotyping system version 2: effects on sensitivity and complexity of the assay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0276-8

Defining treatment failure in resource-rich settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0276-8

Traceability of 3 generations of nucleic acid amplification tests for quantitative HIV-1 RNA measurements to meet the WHO HIV-1 RNA International Standards.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0276-8

The SnoB study: frequency of baseline raltegravir resistance mutations prevalence in different non-B subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0276-8

Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0276-8

The role of compartment penetration in PI-Monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00430-012-0276-8

Detection of HIV type 1 load by the Roche Cobas TaqMan assay in patients with viral loads previously undetectable by the Roche Cobas Amplicor Monitor

21 January 2018

1 reference

12 December 2020

2011 update of the drug resistance mutations in HIV-1.

1 reference

12 December 2020

Mutational patterns in the frameshift-regulating site of HIV-1 selected by protease inhibitors

1 reference

12 December 2020

Comparison of HIV-1 viral load assay performance in immunological stable patients with low or undetectable viremia

1 reference

12 December 2020

The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy

1 reference

12 December 2020

10.1007/S00430-012-0276-8

Identifiers

DOI

1 reference

26 November 2017

1 reference